Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is expected to be posting its results before the market opens on Wednesday, May 13th. Analysts expect Unicycive Therapeutics to post earnings of ($0.4589) per share and revenue of $11.1110 million for the quarter.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.36). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Unicycive Therapeutics Trading Up 1.3%
Shares of NASDAQ UNCY opened at $8.08 on Wednesday. The stock has a market cap of $215.74 million, a price-to-earnings ratio of -3.72 and a beta of 1.78. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The company's 50-day moving average price is $6.91 and its 200 day moving average price is $6.22.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a research note on Friday, May 1st. They issued a "buy" rating and a $22.00 price objective on the stock. Benchmark lowered their price objective on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating on the stock in a research note on Monday, April 6th. Guggenheim lowered their price objective on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, April 2nd. Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Unicycive Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $24.75.
Get Our Latest Report on Unicycive Therapeutics
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC lifted its holdings in Unicycive Therapeutics by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company's stock valued at $7,804,000 after purchasing an additional 652,901 shares in the last quarter. Millennium Management LLC purchased a new position in Unicycive Therapeutics in the 4th quarter valued at about $5,856,000. Vanguard Group Inc. lifted its holdings in Unicycive Therapeutics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company's stock valued at $2,873,000 after purchasing an additional 52,925 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new position in Unicycive Therapeutics in the 4th quarter valued at about $1,154,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company's stock worth $989,000 after acquiring an additional 45,563 shares during the period. 40.42% of the stock is currently owned by hedge funds and other institutional investors.
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
